On September 20, 1938, the German chemist, Dr. Otto Roelen, then the research director at Ruhrchemie in Oberhausen (now Oxea), filed a patent application for the oxo synthesis.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International